Search for mutations in signaling pathways in head and neck squamous cell carcinoma
- Authors:
- Thais Gulim De Carvalho
- Ana Carolina De Carvalho
- Danielle Calheiros Campelo Maia
- Juliana Kaori Ogawa
- Andre Lopes Carvalho
- Andre Luiz Vettore
-
Affiliations: Cancer Molecular Biology Laboratory, Department of Science Biology, Federal University of São Paulo (UNIFESP), 04039‑032, São Paulo, SP, Brazil, Department of Head and Neck Surgery, Barretos Cancer Hospital, 14784-400, Barretos, SP, Brazil - Published online on: May 13, 2013 https://doi.org/10.3892/or.2013.2455
- Pages: 334-340
This article is mentioned in:
Abstract
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
Wong DT, Todd R, Tsuji T and Donoff RB: Molecular biology of human oral cancer. Crit Rev Oral Biol Med. 7:319–328. 1996. View Article : Google Scholar : PubMed/NCBI | |
Carvalho AL, Nishimoto IN, Califano JA and Kowalski LP: Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 114:806–816. 2005. View Article : Google Scholar : PubMed/NCBI | |
Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW and Villaret DB: Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck. 26:984–994. 2004.PubMed/NCBI | |
Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. Science. 260:812–816. 1993. View Article : Google Scholar : PubMed/NCBI | |
Greenman C, Stephens P, Smith R, et al: Patterns of somatic mutation in human cancer genomes. Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI | |
Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C and Tannapfel A: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 22:4757–4759. 2003. View Article : Google Scholar : PubMed/NCBI | |
Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E and Kakolyris S: Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology. 81:259–272. 2011. View Article : Google Scholar : PubMed/NCBI | |
Santarpia L, El-Naggar AK, Cote GJ, Myers JN and Sherman SI: Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 93:278–284. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rowe LR, Bentz BG and Bentz JS: Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol. 60:1211–1215. 2007. View Article : Google Scholar | |
Tie J, Gibbs P, Lipton L, et al: Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 128:2075–2084. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kullmann F, Hartmann A, Stohr R, et al: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 81:3–8. 2011. View Article : Google Scholar | |
Rako I, Jakic-Razumovic J, Caban D, et al: The role of KRAS gene mutation testing in colorectal cancer - a predictive biomarker of response to EGFR inhibitors therapy. Lijec Vjesn. 133:403–407. 2011.(In Croatian). | |
Smilek P, Neuwirthova J, Jarkovsky J, et al: Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma. 59:508–515. 2012. View Article : Google Scholar : PubMed/NCBI | |
Van Damme N, Deron P, Van Roy N, et al: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 10:1892010.PubMed/NCBI | |
Bruckman KC, Schonleben F, Qiu W, Woo VL and Su GH: Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 110:632–637. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rameh LE and Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 274:8347–8350. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lee JW, Soung YH, Kim SY, et al: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI | |
Levine DA, Bogomolniy F, Yee CJ, et al: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI | |
Phillips WA, Russell SE, Ciavarella ML, et al: Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer. 118:2644–2646. 2006. View Article : Google Scholar : PubMed/NCBI | |
Schonleben F, Qiu W, Ciau NT, et al: PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res. 12:3851–3855. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wu G, Mambo E, Guo Z, et al: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 90:4688–4693. 2005. View Article : Google Scholar | |
Constantinescu SN, Girardot M and Pecquet C: Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 33:122–131. 2008. View Article : Google Scholar | |
Flex E, Petrangeli V, Stella L, et al: Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 205:751–758. 2008. View Article : Google Scholar : PubMed/NCBI | |
Walters DK, Mercher T, Gu TL, et al: Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10:65–75. 2006. View Article : Google Scholar : PubMed/NCBI | |
Melzner I, Bucur AJ, Bruderlein S, et al: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 105:2535–2542. 2005. View Article : Google Scholar | |
Jeong EG, Kim MS, Nam HK, et al: Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 14:3716–3721. 2008. View Article : Google Scholar : PubMed/NCBI | |
Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI | |
Rosell R, Moran T, Carcereny E, et al: Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol. 12:75–80. 2010. View Article : Google Scholar : PubMed/NCBI | |
Siddiqui AD and Piperdi B: KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 17:1168–1176. 2010. View Article : Google Scholar : PubMed/NCBI | |
Licitra L, Mesia R, Rivera F, et al: Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 22:1078–1087. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nikiforova MN, Kimura ET, Gandhi M, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 88:5399–5404. 2003. View Article : Google Scholar | |
Mathur A, Moses W, Rahbari R, et al: Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 117:4390–4395. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mori R, Ishiguro H, Kimura M, et al: PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res. 145:320–326. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series. 41:95–98. 1999. | |
Ewing B, Hillier L, Wendl M and Green P: Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 8:175–185. 1998. View Article : Google Scholar : PubMed/NCBI | |
Bianchini C, Ciorba A, Pelucchi S, Piva R and Pastore A: Targeted therapy in head and neck cancer. Tumori. 97:137–141. 2011.PubMed/NCBI | |
Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 11:8418–8424. 2005. View Article : Google Scholar : PubMed/NCBI | |
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS and Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 22:77–85. 2004. View Article : Google Scholar : PubMed/NCBI | |
Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 25:2171–2177. 2007. | |
Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI | |
Burtness B, Goldwasser MA, Flood W, Mattar B and Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bourhis J, Rivera F, Mesia R, et al: Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 24:2866–2872. 2006. View Article : Google Scholar : PubMed/NCBI | |
Loyo M, Li RJ, Bettegowda C, et al: Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 35:454–463. 2012. View Article : Google Scholar : PubMed/NCBI | |
Fujii S, Uryu H, Akashi K, et al: Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. Int J Clin Oncol. Mar 24–2012.(Epub ahead of print). | |
Chang SE, Bhatia P, Johnson NW, et al: Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer. 48:409–412. 1991. View Article : Google Scholar : PubMed/NCBI | |
Cohen Y, Goldenberg-Cohen N, Shalmon B, et al: Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncol. 47:946–950. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mercer KE and Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 1653:25–40. 2003.PubMed/NCBI | |
Lee JW, Yoo NJ, Soung YH, et al: BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer. 89:1958–1960. 2003. View Article : Google Scholar | |
Kobayashi M, Sonobe M, Takahashi T, et al: Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res. 31:4619–4623. 2011.PubMed/NCBI | |
Agrawal N, Frederick MJ, Pickering CR, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157. 2011. View Article : Google Scholar : PubMed/NCBI | |
Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI | |
Qiu W, Schonleben F, Li X, et al: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 12:1441–1446. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kozaki K, Imoto I, Pimkhaokham A, et al: PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 97:1351–1358. 2006. View Article : Google Scholar : PubMed/NCBI | |
Fenic I, Steger K, Gruber C, Arens C and Woenckhaus J: Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep. 18:253–259. 2007.PubMed/NCBI | |
Murugan AK, Hong NT, Fukui Y, Munirajan AK and Tsuchida N: Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol. 32:101–111. 2008.PubMed/NCBI | |
Estilo CL, POC, Ngai I, et al: The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res. 9:2300–2306. 2003.PubMed/NCBI | |
Freier K, Schwaenen C, Sticht C, et al: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 43:60–66. 2007. View Article : Google Scholar : PubMed/NCBI | |
Liu CJ, Lin SC, Chen YJ, Chang KM and Chang KW: Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog. 45:721–731. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hoa M, Davis SL, Ames SJ and Spanjaard RA: Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res. 62:7154–7156. 2002.PubMed/NCBI | |
Lai SY and Johnson FM: Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat. 13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI | |
Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061. 2005. View Article : Google Scholar : PubMed/NCBI | |
Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar | |
Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA and Margaglione M: A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood. 110:2768–2769. 2007. View Article : Google Scholar : PubMed/NCBI |